F-group (family)
223.1.1.3 GAF
Ligands and drugs
842
Member domains
437
with ligand contacts (≤ 4 Å)
51.9% of members
295
with DrugDomain annotations
35.0% of members
92
with a DrugBank compound
10.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 223.1.1.3 belongs to X-group 223 Profilin-like, which binds 8.8 ligand superclasses per 20 proteins, broader than 74% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB18267 | HEM | Ferroheme | 16 |
| DB02527 | CMP | Cyclic adenosine monophosphate | 8 |
| DB02315 | 35G | Cyclic GMP | 7 |
| DB02235 | SME | L-methionine (R)-S-oxide | 4 |
| DB04332 | ETE | 2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol | 4 |
| DB16833 | ADP | Adenosine disphosphate | 4 |
| DB03345 | BME | Mercaptoethanol | 2 |
| DB08357 | P4G | Diethylene glycol diethyl ether | 2 |
| DB11588 | CMO | Carbon monoxide | 2 |
| DB00142 | GLU | Glutamic acid | 1 |
| DB00820 | — | Tadalafil | 1 |
| DB06246 | — | Exisulind | 1 |
| DB08811 | — | Tofisopam | 1 |
| DB14756 | SRT | meso-Tartaric acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| LBV | 3-[2-[(Z)-[3-(2-carboxyethyl)-5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-4-methyl-pyrrol-1-ium-2-ylidene]methyl]-5-[(Z)-[(3E)-3-ethylidene-4-methyl-5-oxidanylidene-pyrrolidin-2-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid | 138 |
| BLA | BILIVERDINE IX ALPHA | 75 |
| CYC | PHYCOCYANOBILIN | 47 |
| CL | CHLORIDE ION | 33 |
| EL5 | 3-[(2Z)-2-({3-(2-carboxyethyl)-5-[(E)-(4-ethenyl-3-methyl-5-oxo-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl}methylidene)-5-{(Z)-[(3E,4S)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl}-4-methyl-2H-pyrrol-3-yl]propanoic acid | 25 |
| O6E | 3-[5-[[(3~{R},4~{R})-3-ethyl-4-methyl-5-oxidanylidene-3,4-dihydropyrrol-2-yl]methyl]-2-[[5-[(4-ethyl-3-methyl-5-oxidanylidene-pyrrol-2-yl)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1~{H}-pyrrol-2-yl]methyl]-4-methyl-1~{H}-pyrrol-3-yl]propanoic acid | 17 |
| PCG | CYCLIC GUANOSINE MONOPHOSPHATE | 17 |
| HEM | PROTOPORPHYRIN IX CONTAINING FE | 16 |
| BLR | 3-[5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[[5-[(Z)-(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid | 12 |
| JRA | 3-[2-[(~{Z})-[5-[(~{Z})-[(3~{S},4~{R})-3-ethenyl-4-methyl-5-oxidanylidene-pyrrolidin-2-ylidene]methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-pyrrol-2-ylidene]methyl]-5-[(~{Z})-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-4-methyl-1~{H}-pyrrol-3-yl]propanoic acid | 12 |
| CMP | ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE | 10 |
| VRB | Phycoviolobilin, blue light-absorbing form | 10 |
| MGmetal | MAGNESIUM ION | 9 |
| CAmetal | CALCIUM ION | 8 |
| 35G | GUANOSINE-3',5'-MONOPHOSPHATE | 7 |
| NAmetal | SODIUM ION | 7 |
| JQ2 | 3-[2-[(~{Z})-[12-ethyl-6-(3-hydroxy-3-oxopropyl)-13-methyl-11-oxidanylidene-4,10-diazatricyclo[8.3.0.0^{3,7}]trideca-1,3,6,12-tetraen-5-ylidene]methyl]-5-[(~{Z})-(3-ethyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-4-methyl-1~{H}-pyrrol-3-yl]propanoic acid | 5 |
| 3Q8 | 3-[2-[[5-[[(3E,4S)-3-ethylidene-4-methyl-5-oxidanylidene-pyrrol-2-yl]methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethyl-3-methyl-5-oxidanylidene-pyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid | 4 |
| ETE | 2-{2-[2-2-(METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL | 4 |
| LBW | 3-[2-[(Z)-[5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-pyrrol-1-ium-2-ylidene]methyl]-5-[(Z)-[(3E,4R)-3-ethylidene-4-methyl-5-oxidanylidene-pyrrolidin-2-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid | 4 |